Black Diamond Therapeutics
Our MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat CNS disease. Our efforts are focused on non-small cell lung cancer (NSCLC) and glioblastoma (GBM). Cancer is a complex and ever-evolving disease, yet current targeted therapies address a limited subset of oncogenic mutations.
Basic Information
- Category: Oncology Biotech
- Founded: 2014
- Headquarters: Cambridge, MA
- Website: blackdiamondtherapeutics.com
Documented Facts
- Email: partnership@bdtx.com (No linked source recorded for this statement.)
- Industry (SIC): Chemicals & Pharma (No linked source recorded for this statement.)
- Stock ticker: BDTX (Nasdaq) (No linked source recorded for this statement.)
Evidence and Sources
- Black Diamond Therapeutics — Official Site (official)
- Black Diamond Therapeutics on linkedin (social)
- Black Diamond Therapeutics, Inc. — SEC EDGAR (reference)
Citation Guidance
Explore Oncology Biotech profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Black Diamond Therapeutics.
- Canonical profile: https://brandsource.ai/brands/black-diamond-therapeutics
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/black-diamond-therapeutics/json-ld
- Citation profile API: https://brandsource.ai/api/brands/black-diamond-therapeutics/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (91/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-27T08:35:03.246Z
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Our MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat CNS disease. Our efforts are focused on non-small cell lung cancer (NSCLC) and glioblastoma (GBM). Cancer is a complex and ever-evolving disease, yet current targeted therapies address a limited subset of oncogenic mutations.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 3 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.